Among these, EGFR and MSLN seem to be the more promising targets compared to others: indeed, they showed higher antigen specificity and lower on-target, off-tumor toxicity concern, i.e., the potential healthy organ toxicity, due to the expression of these targets in tissues other than tumor [304]. This evidence concerns the gene EGFR and neoplasm.